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Abstract   
Background: Young adults with acute myocardial infarction are a critical group 
to examine for the purpose of risk factor stratification and modification. In this 
study we aimed to assess the clinical utility of the adjusted Global 
AntiphosPholipid Syndrome Score (aGAPSS) for the risk stratification of acute 
myocardial infarction in a cohort of young patients with antiphospholipid 
syndrome (APS). 
Methods: The analysis included 83 consecutive APS patients (≤ 50 years old) 
who presented with arterial or venous thromboembolic events. Data on 
cardiovascular risk factors and antiphospholipid antibodies (aPL) positivity 
were retrospectively collected. The aGAPSS was calculated by adding the points 
corresponding to the risk factors, based on a linear transformation derived from 
the ß regression coefficient as follows: 3 for hyperlipidaemia, 1 for arterial 
hypertension, 5 for aCL IgG/IgM, 4 for anti-b2 glycoprotein I IgG/IgM and 4 for 
LA. 
Results: Higher aGAPSS values were observed in patients with acute myocardial 
infarction when compared to the others [mean aGAPSS 11.9 (S.D. 4.15, range 4-
18) Vs. (mean aGAPSS 9.2, S.D. 5.1, range 1-17); T test:p<0.05]. Significantly 
higher aGAPSS values were also seen in patients with acute coronary syndrome 
compared to patients with a history of peripheral or cerebrovascular arterial 
thrombotic events [mean aGAPSS 11.9 (S.D. 4.15, range 4-18) Vs. (mean aGAPSS 
6.7, S.D. 5.7, range 1-17); T test: P<0.005]. 
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Conclusions:  
The aGAPSS is based upon a quantitative score and could aid risk stratifying APS 
patients younger than 50 years for the likelihood of developing coronary 
thrombotic events and may guide pharmacological treatment for high-risk 
patients. 
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1.1 Introduction 
Acute myocardial infarction amongst young patients (for the purpose of this 
work ‘young’ refers to adults younger than 50 years old) is an uncommon event. 
However, it might represent a life threating situation being associated with a 
significantly increased mortality and morbidity[1,2]. Epidemiological studies 
have demonstrated that younger adults who develop acute coronary syndrome 
have an increased prevalence of cardiovascular risk factors, including male 
gender, smoking, family history of cardiovascular events and [1–3].Conversely, 
these patients present a lower prevalence of hypertension and diabetes[2,3]. 
Angiography is more likely to show a reduced coronary atherosclerosis when 
compared with older patients with cardiovascular events [2]. In the setting of 
underlying systemic autoimmune diseases, premature cardiovascular disease 
(CVD) deserves even more attention as conditions such as systemic lupus 
erythematosus (SLE) or rheumatoid arthritis (RA) have been associated with the 
development of premature CVD [4]. The latter has even been implemented in the 
national institute of health and care excellence (NICE) screening questions to 
risk stratify patients for the development of CVD[5].  
Young adults are a critical group to examine for the purpose of risk factor 
stratification and modification. In this particular patient group, a thorough 
history for conventional risk factors including a family history for inherited 
thrombophilias and often also investigations for any underlying acquired 
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thrombophilia should be warranted as positive results might have an impact on 
the therapeutic choices [6]. 
The most common acquired thrombophilia is antiphospholipid syndrome (APS), 
an autoimmune disorder characterized by arterial and venous thrombosis 
and/or pregnancy morbidity in the presence of  persistent positivity for aPL[7]. 
The current classification criteria for APS include three laboratory tests: lupus 
anticoagulant (LA), anticardiolipin (aCL) and anti-β2 glycoprotein-I (β2GPI). To 
prevent the detection of transient antibodies, tests must be positive on more 
than 2 occasions, at least 12 weeks apart[7].  
To date, identifying patients with aPL who are at higher risk for developing any 
thrombotic event is still an unmet clinical need and remains a major challenge 
for the treating physician.  Recently, our group conceived a risk score for clinical 
manifestations of APS [the global APS score (GAPSS)] that takes into account the 
combination of independent cardiovascular risk factors and the aPL positivity 
profile [8]. The aim of our study was to assess the clinical utility of the adjusted 
GAPSS (aGAPSS) score for risk stratification of acute myocardial infarction 
occurrence in a cohort of young patients with thrombotic events.  
2.1 Patients and methods:   
2.2 Patients 
This retrospective study included 83 consecutive APS patients who attended the 
Giovanni Bosco Hospital, Turin, Italy and the Louise Coote Lupus Unit at St 
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Thomas’ Hospital, London, UK. Inclusion criteria included: a) history of 
thrombotic APS (venous and/or arterial) and b) age ≤ 50 years old at the time of 
the first event. Patients with myocardial infarction aged ≤ 50 years old are 
routinely checked for aPL in both centres as part of the good clinical practice. 
When found positive, aPL testing was repeated at least 12 weeks apart. The 
patients included in the analysis had a persistent aPL positivity and fulfilled the 
Sydney criteria for APS [7].Fifty-three patients had at least one episode of 
arterial thrombosis (60%), 44 (50%) had at least one episode of venous 
thrombosis. Thirteen patients (15%) had a history of acute myocardial 
infarction. The diagnosis of acute myocardial infarction was based on typical 
chest pain at rest lasting for >20 min and/or electrocardiogram changes and 
dynamic changes in troponin levels according to international standards [9]. A 
diagnosis of acute coronary syndrome was confirmed by percutaneous coronary 
intervention. Demographic, clinical and laboratory characteristics are 
summarized in Table 1.  
2.3 Cardiovascular risk factors assessment 
Cardiovascular risk factors (including hypertension, dyslipidaemia, diabetes, 
hormone replacement therapy and smoking) were assessed following the 
National Institute for Health and Care Excellence (NICE) guidelines [5]. In detail, 
enrolled patients underwent a physical examination, blood pressure 
determination and phlebotomy for vascular risk factors. Arterial hypertension 
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was defined as an appropriately sized cut-off (140/90 mmHg or higher) [5], high 
blood pressure on at least two occasions or use of oral antihypertensive 
medications. Serum total and high-density lipoprotein (HDL) cholesterol levels 
were determined with standardized enzymic methods and interpreted 
according to current cut-off values [5]. For patients with acute myocardial 
infarction, underlying atrial fibrillation was ruled out in with 24h Holter 
monitoring.  
2.4 Autoantibody detection 
The aPL profile included aCL, LA and anti-ß2 glycoprotein I (anti-ß2GPI) 
antibodies. The aCL and anti-ß2GPI were detected by ELISA as described 
previously [10,11]. Plasma samples were tested for the presence of LA according 
to the recommended criteria from the International Society on Thrombosis and 
Haemostasis (ISTH) Subcommittee on Lupus Anticoagulant/Phospholipid-
Dependent Antibodies [12][13]. 
2.5 Adjusted GAPSS calculation 
The cumulative aGAPSS was calculated for each patient as previously reported 
by adding together all points corresponding to the risk factors [14]. 
In brief, the GAPSS was developed and validated in 211 consecutive SLE patients 
who were randomly divided into two sets by a computer-generated randomized 
list. Data on clinical disease manifestations, conventional cardiovascular risk 
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factors, aPL profile, antinuclear antibodies (ANA), extractable nuclear antibodies 
(ENA)and antibodies against double stranded DNA (anti-dsDNA) were collected 
and included in the analysis. We developed the GAPSS in the first set of patients 
(n = 106), assigning the risk factors identified by multivariate analysis and 
weighted points proportional to the ß regression coefficient values. Assigned 
points to risk factors based on this linear transformation of the corresponding ß 
regression coefficient were 3 for hyperlipidaemia, 1 for arterial hypertension, 5 
for aCL IgG/IgM, 4 for anti-b2GPI IgG/IgM, 3 for aPS-PT IgG/IgM and 4 for LA. 
The GAPSS was then validated in a second set of patients with SLE (n = 
105)[8]and in a third set of patients with primary APS (n = 62)[15]. The GAPSS 
was further applied and validated by two independent groups [16][17].In order 
to increases the generalizability of the findings, a complementary analysis was 
applied in this cohort of patients by using an adjusted version of the score. This 
included only aPL testing included in the current classification criteria for APS 
(excluding aPS-PT, not routinely available in all the laboratories). Data are 
presented as adjusted GAPSS (aGAPSS). For the purpose of this study, all 
computed variables refer to values/parameters assessed within one year from 
the occurrence of the thrombotic event.  
2.6 Statistical analysis 
Categorical variables are presented as number (%) and continuous variables are 
presented as mean (S.D.). The significance of baseline differences was 
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determined by the chi-squared test, Fisher’s exact test or the unpaired t-test, as 
appropriate. A two-sided P-value <0.05 was statistically significant. All statistical 
analyses were performed using SPSS version 19.0 (IBM, Armonk, NY, USA).  
3.1 Results:  
A total of 83 consecutive APS patients (age ≤50 years old at the time of the first 
event, mean 44,6 (SD 11,3), female 90%) with a history of previous thrombotic 
events (60% arterial and 50% venous) were included in the analysis. Thirty-one 
patients fulfilled the current classification criteria for primary APS (PAPS), while 
in the remaining 52 patients APS was associated with SLE (secondary APS; 
SAPS). Thirteen patients (15%) had a history of acute myocardial infarction. Of 
note, 6 of those 13 patients (46%) had also an history of ischemic stroke. Among 
patients with a history of myocardial infarction, no statistical difference (in 
terms of age, sex, aPL profile, cardiovascular risk factors, treatments, previous 
history of thrombotic events) was found between PAPS and SAPS. Patients with 
acute coronary syndrome presented a mean aGAPSS of 11.9 (S.D. 4.15, range 4-
18). Significantly higher aGAPSS values were seen in patients with acute 
myocardial infarction when compared with those with history of any other 
thrombotic events [mean aGAPSS 11.9 (S.D. 4.15, range 4-18) Vs. (mean aGAPSS 
9.2, S.D. 5.1, range 1-17); T test p:<0.05].Significantly higher aGAPSS values were 
also seen when comparing patients with acute coronary syndrome with patients 
with a history of peripheral or cerebrovascular arterial thrombotic events [mean 
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aGAPSS 11.9 (S.D. 4.15, range 4-18) Vs. (mean aGAPSS 6.7, S.D. 5.7, range 1-17); 
T test: p <0.005]. When separating for cardiovascular risk factors, 
hypercholesterolemia was significantly higher in the group that developed 
myocardial infarction compared with patients with a history of any thrombosis 
and patients with history of arterial thrombotic events (Chi square test: p< 
0.0001 and p< 0.0001). Furthermore, when evaluating the aPL positivity profiles 
in the different cohorts, we found significantly higher rate of multiple positivity 
(more than one aPL) for LA, aCL (IgG/IgM), anti-ß2GPI antibodies (IgG/IgM) in 
the group that developed myocardial infarction compared with patients with a 
history of any other arterial thrombotic event alone (Chi square test: p<0.05 for 
all aPL). However, when focusing on the so-called triple positivity, we failed to 
observed any statistical difference when comparing patients with acute 
myocardial infarction with those with other thrombotic manifestations  (Table 
2). 
No statistical significant differences were observed when comparing separately 
each cardiovascular risk factor (smoking, diabetes, arterial hypertension) nor 
other thrombotic risk factor (hormonal therapy, immobilization, surgery, 
malignancy).  
4.1 Discussion:   
In this study we demonstrate the clinical relevance of the aGAPSS for risk 
stratification in young patients with acute myocardial infarction. Our cohort 
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comprehended 83 young patients (≤ 50 years old) who had experienced at least 
one thrombotic events (arterial and/or venous). 
Our group recently published a comprehensive series of studies developing and 
validating the global APS score (GAPSS) in different patients populations[8]. The 
GAPSS model was developed in patients with SLE and higher GAPSS scores were 
observed in patients who experienced thrombosis and/or pregnancy loss 
compared with those without clinical events. Moreover, the GAPSS score was 
evaluated in a subsequent prospective study of 51 SLE patients10 and in 62 
consecutive patients with primary APS[18]. The GAPSS model was further 
applied and validated by two independent groups, confirming that higher GAPSS 
values were seen in patients who had clinical APS manifestations (such as 
thrombosis or pregnancy complications) compared to patients without APS 
manifestations[16][17]. In the original GAPSS, anti-
phosphatidylserine/prothrombin antibodies (aPS-PT) were included in the 
score. However, these are not currently part of the international consensus 
classification criteria [7]. Moreover, aPS-PT antibodies are not routinely tested 
in most clinical laboratories, and the inclusion as part of the score might be of 
concern to many. To address this concern, in our current study we applied the 
adjusted GAPSS(excluding aPS-PT) demonstrating its clinical utility for the 
stratification of patients for their rate of thromboembolic events [14]. 
Furthermore, we showed that higher aGAPSS values are seen in patients who 
experienced acute myocardial infarction when compared to those with 
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thrombosis alone. In addition, when stratifying the patients and analyzing those 
patients who developed at least one arterial thromboembolic event, the aGAPSS 
was significantly higher in patients who experienced acute myocardial 
infarction. When comparing patients with PAPS and SAPS who suffered from 
myocardial infarction, no differences were observed in demographic, clinical or 
laboratory characteristics. It has been shown that in young patients who develop 
acute coronary syndrome, despite having a high rate of cardiovascular risk 
factors, angiographic data indicate a less prominent atherosclerosis compared to 
general population [1-3]. Our results are in line with these findings, showing an 
increased proportion of patients with hyperlipidemia in the patients who 
developed acute coronary syndrome, despite the fact that there were no 
significant differences between groups with regards to the presence of arterial 
hypertension. Thus, there is growing interest and necessity of thrombophilia 
screening and aPL testing in young patients who develop myocardial infarction. 
Besides, one should consider that it was not among the scopes of this study to 
assess the prevalence of aPL in a cohort of young patients with myocardial 
infarction. Our analysis supports the idea that a combination of aPL tests should 
be warranted when assessing the risk of acute coronary syndrome in young 
patients. Furthermore, in these patients, the aGAPSS might represents a 
substantial tool in quantifying the risk for acute myocardial infarction, 
potentially impacting on therapeutic long-term choices and options. Indeed, 
while anti-platelets agents are the gold standard therapies in acute coronary 
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syndrome in the general population, there is still a debated whether APS 
patients with arterial thrombosis should undergo long-term anticoagulation 
(and more critically, the intensity of such anticoagulation) as best treatment 
option. This aspect is currently highly debated and it was matter of discussion 
during the 14th International Congress on aPL Task Force [19–23] and in the 
more recent 15th International Congress on aPL Task Force [24]. The prevalence 
of aPL in the general population is estimated to be between 1 and 5 % [25]. 
Multiple studies have investigated the association of aPL and acute myocardial 
infarction [26][27][28][29][30][31][32][33](Table 3). Among other, recently 
Andreoli and colleagues found an estimated frequency of 11% in patients with 
myocardial infarction in aPL positive patients [34]. However, the true incidence 
of APS among survivors of acute coronary syndrome is difficult to estimate in 
such a rare condition.  
We acknowledge few limitations for our study. Firstly, the use of a cross-
sectional approach generally provides only a ‘snapshot’ and it may therefore be 
possible that individual scores would give a different aGAPSS when conducted at 
a different point of time. A future prospective validation of our findings in the 
specific setting of acute coronary syndrome is highly needed. However, one 
should acknowledge that APS is a rare condition and acute coronary syndrome 
represents about 5%[35] of the clinical presentation of this condition. While a 
longitudinal study would be very informative to confirm our findings, a 
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prospective data collection may be challenging and would requires international 
joint efforts. From that perspective, it is worth mentioning the AntiPhospholipid 
syndrome alliance for clinical trials and International networking (APS ACTION) 
is the first-ever international research network that has been created 
specifically to design and conduct well-designed, large-scale, multicenter clinical 
studies in persistently aPL-positive patients [34,36–38]. 
Finally, the effect of therapy and therapy compliance, a significant variable when 
evaluating risk, could not be assessed, as treatment was not controlled in this 
cohort, but varied according to the clinical manifestations and the clinician’s 
judgement. 
In the future, with prospective studies confirming our findings, aGAPSS might be 
a valid tool for the risk quantification of acute myocardial infarction in young 
patients ≤ 50 years old. The aGAPSS is based upon a quantitative score and will 
aid risk stratifying patients < 50 years for the likelihood of developing coronary 
thrombotic events and may consequently guide pharmacological treatment for 
high-risk patients.  
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